Immunological aspects of the antiphospholipid syndrome;Aspects immunologiques du syndrome des antiphospholipides

Revue de Medecine Interne

Volumn 33, Issue 4, 2012, Pages 189-193

  Pasquali, J L ^a,b   Sibilia, J ^c   Poindron, V ^a,b   Korganow, A S ^a,b   Soulas Sprauel, P ^a,b   Martin, T ^a,b  

^a HÔPITAL CIVIL   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Antiphospholipid syndrome; Autoantibodies

Indexed keywords

AUTOANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; DISEASE ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; SHORT SURVEY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; IMMUNOLOGIC FACTORS; RISK ASSESSMENT; RISK FACTORS;

EID: 84858745429     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2011.08.008     Document Type: Short Survey

References (32)

1. Pasquali J.L., Poindron V., Korganow A.S., Martin T. The antiphospholipid syndrome. Best Pract Res Clin Rheumatol 2008, 22:831-845.
2. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990, 87:4120-4124.
3. Erkan D., Zhang H.W., Shriky R.C., Merrill J.T. Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 2002, 11:215-220.
4. Bevers E.M., Galli M., Barbui T., Comfurius P., Zwaal R.F. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991, 66:629-632.
5. Ogawa H., Zhao D., Dlott J.S., Cameron G.S., Yamazaki M., Hata T., et al. Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities. Am J Clin Pathol 2000, 114:619-628.
6. Chen P.P., Giles I. Antibodies to serine proteases in the antiphospholipid syndrome. Curr Rheumatol Rep 2010, 12:45-52.
7. Urbanus R.T., de Laat B. Antiphospholipid antibodies and the protein C pathway. Lupus 2010, 19:394-398.
8. Hunt J.E., Simpson R.J., Krilis S.A. Identification of a region of beta2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A 1993, 90:2141-2145.
9. Price B.E., Rauch J., Shia M.A., Walsh M.T., Lieberthal W., Gilligan H.M., et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol 1996, 157:2201-2208.
10. Lieby P., Soley A., Levallois H., Hugel B., Freyssinet J.M., Cerutti M., et al. The clonal analysis of anticardiolipin antibodies in a single patient with primary antiphospholipid syndrome reveals an extreme antibody heterogeneity. Blood 2001, 97:3820-3828.
11. Lin W.S., Chen P.C., Yang C.D., Cho E., Hahn B.H., Grossman J., et al. Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007, 56:1638-1647.
12. Lieby P., Soley A., Knapp A.M., Cerutti M., Freyssinet J.M., Pasquali J.L., et al. Memory B cells producing somatically mutated antiphospholipid antibodies are present in healthy individuals. Blood 2003, 102:2459-2465.
13. Lambrianides A., Giles I.P. Use of monoclonal antibodies to dissect specificity and pathogenesis of antiphospholipid antibodies. Lupus 2010, 19:359-364.
14. Pierangeli S.S., Liu X., Espinola R., Olee T., Zhu M., Harris N.E., et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000, 84:388-395.
15. Lieby P., Poindron V., Roussi S., Klein C., Knapp A.M., Garaud J.C., et al. Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack. Blood 2004, 104:1711-1715.
16. Pasquali J.L., Soulas-Sprauel P., Korganow A.S., Martin T. Auto-reactive B cells in transgenic mice. J Autoimmun 2007, 29:250-256.
17. Li H., Jiang Y., Cao H., Radic M., Prak E.L., Weigert M. Regulation of anti-phosphatidylserine antibodies. Immunity 2003, 18:185-192.
18. Kuwana M., Matsuura E., Kobayashi K., Okazaki Y., Kaburaki J., Ikeda Y., et al. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005, 105:1552-1557.
19. Pierangeli S.S., Vega-Ostertag M.E., Raschi E., Liu X., Romay-Penabad Z., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007, 66:1327-1333.
20. Raschi E., Borghi M.O., Grossi C., Broggini V., Pierangeli S., Meroni P.L. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008, 17:937-942.
21. Rand J.H., Wu X.X. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999, 82:649-655.
22. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., McCrae K.R., Bovill E.G., et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003, 163:1193-1200.
23. Brachvogel B., Dikschas J., Moch H., Welzel H., von der Mark K., Hofmann C., et al. Annexin A5 is not essential for skeletal development. Mol Cell Biol 2003, 23:2907-2913.
24. Xu C., Mao D., Holers V.M., Palanca B., Cheng A.M., Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000, 287:498-501.
25. Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211-220.
26. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003, 112:1644-1654.
27. Thurman J.M., Kraus D.M., Girardi G., Hourcade D., Kang H.J., Royer P.A., et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 2005, 42:87-97.
28. Berman J., Girardi G., Salmon J.E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005, 174:485-490.
29. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Mackman N., et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood 2007, 110:2423-2431.
30. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
31. Lambrianides A., Carroll C.J., Pierangeli S.S., Pericleous C., Branch W., Rice J., et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010, 184:6622-6628.
32. Di Simone N., Meroni P.L., de Papa N., Raschi E., Caliandro D., De Carolis C.S., et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000, 43:140-150.